AI Driven, Computational Pathology

Our platform combines a unique approach to bring together all the key elements of biologically aware artificial intelligence (AI) to deliver the spatialomics revolution to the clinician and enable individualized, patient-centric decision-making.

The TissueCypher® platform employs sophisticated computer algorithms to objectively and simultaneously quantify multiple key system biomarkers, extracting high-dimensional data that is integrated into individual decision-making indices. Physicians use these indices to make better decisions on patient management. 

Our scientific publications and conference presentations offer a comprehensive view of our spatial biology capabilities, including the worlds’ first precision medicine test that objectively and independently predicts the development of esophageal cancer in patients with Barrett’s esophagus (BE).

Cernostics Intellectual Property

Cernostics’ technology and products are protected by or associated with applications, publications, and/or patents that are posted on the Internet to provide notice to the public. This list is provided in compliance with the virtual patent marking provisions of 35 U.S.C. §287. Content of this list is updated from time to time but may not be up to date at the specific time you visit this link. Patent applications may be pending or published, and patents may have issued in the United States and elsewhere which are not identified on this list. This list may be unavailable from time to time without notice as part of maintenance or an unintended outage. Efforts will be made to maintain this link page active. The absence of any property from this list does not prevent enforcing any and all legal rights associated with the property.

TissueCypher® Technology & TissueCypher® Barrett’s Esophagus Assay

Patents: U.S. Patent No. 8,114,615; U.S. Patent No. 8,597,899; U.S. Patent No. 10,018,631; Canada Patent No. 2652562; Japan Patent No. 5406019; Japan Patent No.  5888521; Australia Patent No. 2012229102; Additional Patent Applications pending in U.S., Canada, Australia, Israel, and Europe.

Trademark: U.S. Reg. No. 5078325